Source link : https://www.newshealth.biz/health-news/trastuzumab-duocarmazine-tried-in-her2-breast-cancer/
TOPLINE: Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in the experimental group. METHODOLOGY: T-Duo is a third-generation HER2-targeted antibody-drug conjugate designed to treat HER2–positive […]
Author : News Health
Publish date : 2024-10-31 11:49:06
Copyright for syndicated content belongs to the linked Source.
